Samuraciclib - CAS 1805833-75-3

Samuraciclib (CT7001) is a potent, selective, and orally active CDK7 inhibitor with an ATP-competitive nature, effectively inhibiting CDK7 with an IC50 of 41 nM. It demonstrates 45-fold, 15-fold (IC50 of 578 nM), 230-fold, and 30-fold selectivity over CDK1, CDK2, CDK5, and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values of 0.2-0.3 μM and possesses anti-tumor effects [1] [2].

Others, Apoptosis, CDK

Cell Cycle/Checkpoint, Others, Apoptosis

1805755

C22H30N6O

394.51

N(CC1=CC=CC=C1)C=2N3C(=C(C(C)C)C=N3)N=C(NC[C@@H]4[C@@H](O)CNCC4)C2

-20°C

Ice Packs

Small Compound